Last reviewed · How we verify

NCT05882981

Increased Femoral Anteversion and Physical Performance

Completed Last updated 17 January 2024
What this trial tests

trial testing Sit and reach test in High Femoral Anteversion in 44 participants. Completed in 14 January 2024.

Timeline
20 October 2023
Primary endpoint
20 December 2023
14 January 2024

Quick facts

Lead sponsorBezmialem Vakif University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment44
Start date20 October 2023
Primary completion20 December 2023
Estimated completion14 January 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Bezmialem Vakif University

Who can join

Adults 17 to 26, any sex, with High Femoral Anteversion or Muscle Strength. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is important to determine how high femoral anteversion, which is one of the lower extremity malalignments, affects physical performance and to what extent it affects the daily life of the individual. As far as we know, there is no study on this subject except for a study conducted by Staheli et al. in 1977. Therefore, the investigators planned to determine whether and to what extent high femoral anteversion has an effect on physical performance in healthy young adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bezmialem Vakif University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05882981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing